1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Urinary Bladder Cancer: new trials by email Literature Review of Urinary Bladder Cancer trials Research Report on Urinary Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study nivolumab 480mg, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg - Urinary Bladder Cancer, Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2019-01-07 | 2022-08-12 |
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Urinary Bladder Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Capecitabine (1) · Ipilimumab (1) · Mitomycin (1) · Nivolumab (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
Netherlands (1)